

N.B. The English text is an in-house translation

Information about proposed board of directors – annual general meeting 2011 (revised version)

Proposal for re-election of the current members of the board of directors:

Bo Jesper Hansen

Chairman

Born 1958. MD with a Ph.D. from Copenhagen University. Board member as of January 2010. Board member of Gambro AB, MipSalus, TopoTarget A/S and Zymenex A/S. Has previously held various executive positions in Swedish Orphan International AB since 1993, CEO 1998-2010. Founder of Scandinavian Medical Research, through which he worked as medical advisor for Synthelabo, Yamanouchi and Pfizer.

Shares: 7 115 077

Warrants: 0

Dependent in relation to the company and its management but independent in relation to the company's principal shareholder.

Adine Grate Axén

Born 1961. MBA from Stockholm School of Economics. Harvard AMP. Board member since 2010. Chairman of the Listing Committee of Nasdaq OMX Stockholm. Board member of EDB Business Partners (member and chairman of the Audit committee) and Swedavia. Advisor and working board member of 3 Scandinavia. Member of the Commission for the sale of shares in companies with state ownership until this was closed in 2010. 1994 - 2007 various senior management positions within Investor AB and member of the management group 1999 - 2007.

Shares: 0

Warrants: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Lennart Johansson

Born 1955. MBA from Stockholm School of Economics. Board member since 2010. Member of the management team and head of the Operating Investment group at Investor AB. Board member in Mölnlycke AB and Gambro AB. Previously CEO in b-business partners och Emerging Technologies AB.

Shares: 10 000

Warrants: 0

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

N.B. The English text is an in-house translation

Hans Wigzell

Born 1938. Med Dr. h.c. , Ph. D. Professor Immunology. Board member since 2004. Member of the Royal Swedish Academy of Sciences and the Royal Swedish Academy of Engineering Sciences. Board Member of the Karolinska Development AB (Chairman), RaySearch AB, Rhenman and Partner Asset Management (Chairman), Intercell AG, HuMabs AG and AVI Biopharma. President of Karolinska Institutet 1995-2003.

Shares: 180 000

Warrants: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Proposal for election of new member of the board of directors:

Helena Saxon

Born 1970. MBA from Stockholm School of Economics, IMD Lausanne. Member of Investor AB's investment organization within the health care sector. Deputy Board Member in Gambro. Former CFO in Hallvarsson & Halvarsson and Synchron International. A number of positions within Investor AB.

Shares: 0

Warrants: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Hans GCP Schikan

Born 1958. Pharm.D., University of Utrecht. Chief Executive Officer of Prosensa, the Netherlands. Executive Board member Top Institute Pharma. Member of Advisory Board BioScience Park Leiden. Former President of Dutch Association of the Innovative Pharmaceutical Industry, Nefarma. Previously, various senior management positions within former Organon and Genzyme, including Vice President for Global Marketing and Strategy for Genzyme's orphan product portfolio for rare diseases.

Shares: 0

Warrants: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.